JP2024507991A5 - - Google Patents

Info

Publication number
JP2024507991A5
JP2024507991A5 JP2023552197A JP2023552197A JP2024507991A5 JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5 JP 2023552197 A JP2023552197 A JP 2023552197A JP 2023552197 A JP2023552197 A JP 2023552197A JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
dosage form
acceptable salt
combination
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017963 external-priority patent/WO2022183029A1/en
Publication of JP2024507991A publication Critical patent/JP2024507991A/ja
Publication of JP2024507991A5 publication Critical patent/JP2024507991A5/ja
Pending legal-status Critical Current

Links

JP2023552197A 2021-02-26 2022-02-25 激越を処置するための方法及び組成物 Pending JP2024507991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154281P 2021-02-26 2021-02-26
US63/154,281 2021-02-26
PCT/US2022/017963 WO2022183029A1 (en) 2021-02-26 2022-02-25 Methods and compositions for treating agitation

Publications (2)

Publication Number Publication Date
JP2024507991A JP2024507991A (ja) 2024-02-21
JP2024507991A5 true JP2024507991A5 (https=) 2025-03-03

Family

ID=83048476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552197A Pending JP2024507991A (ja) 2021-02-26 2022-02-25 激越を処置するための方法及び組成物

Country Status (7)

Country Link
US (2) US20240139169A1 (https=)
EP (1) EP4297871A4 (https=)
JP (1) JP2024507991A (https=)
CN (1) CN117412747A (https=)
CA (1) CA3208828A1 (https=)
TW (1) TW202302094A (https=)
WO (1) WO2022183029A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
EP4078055B1 (en) * 2019-12-16 2025-03-12 Northwestern University Method for forming a circular pellet
TW202416979A (zh) * 2022-08-31 2024-05-01 美商百歐克斯賽爾治療公司 用於治療急性壓力症之方法及組合物
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024211911A1 (en) * 2023-04-07 2024-10-10 Oaktree Fund Administration, Llc Methods for treating depressive states
EP4731214A1 (en) * 2023-06-23 2026-04-29 BioXcel Therapeutics, Inc. Dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
MX2010001218A (es) * 2007-08-01 2010-04-07 Medivation Neurology Inc Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
EP2340254B8 (en) * 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
TR200903014A1 (tr) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US20120202823A1 (en) * 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes

Similar Documents

Publication Publication Date Title
JP2024507991A5 (https=)
US9782403B2 (en) Treating sexual desire disorders with flibanserin
JP6491174B2 (ja) ニタゾキサニドの制御放出医薬配合物
JP5553452B2 (ja) ブリバラセタムを含む医薬組成物
CN101384545B (zh) 氘化的儿茶酚胺衍生物及包含所述化合物的药物
AU2011290614B2 (en) Nalbuphine-based formulations and uses thereof
EP2921170A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
TW200900094A (en) Solid preparation
JP7137850B2 (ja) バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
JP2023551427A (ja) 口腔粘膜送達のための急速注入組成物及び方法
JPH08505379A (ja) パーキンソン病およびパーキンソン病症候群の治療のためのカルバマゼピンおよびオキカルバゼピンの用途
US20050239798A1 (en) Method for the treatment of premenstrual and other female sexual disorders
JP2020523335A5 (https=)
EP2496217B1 (en) Direct compression tablets of otilonium
CN100379416C (zh) 稳定的口服固体药物组合物
US20220296553A1 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
JP2022504181A5 (https=)
CN111065384A (zh) 扑热息痛的口腔崩解膜组合物
WO2021261837A1 (ko) 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
ES2617657T3 (es) Derivado de metastina y uso del mismo
WO2018062685A1 (ko) 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제
CN116036079B (zh) 一种复合物的药物组合物及其制备方法
CN1112929C (zh) 含有咪唑拉汀的缓释药物制剂
EP2802311B1 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
CN101663035A (zh) 4－环丙基甲氧基－n－(3,5－二氯代－1－环氧－吡啶－4－基)－5－(甲氧基)吡啶－2－甲酰胺用于治疗与帕金森症有关的运动障碍的用途